These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15704477)

  • 1. [Cognitive dysfunction in patients with Parkinson's disease].
    Zakharov VV; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):13-9. PubMed ID: 15704477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline for the treatment of Parkinson's disease.
    Carr J; Kies B; Fine J;
    S Afr Med J; 2009 Oct; 99(10):755-6, 758. PubMed ID: 20128276
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for Parkinson's disease.
    Cranwell-Bruce LA
    Medsurg Nurs; 2010; 19(6):347-9, 355; quiz 350. PubMed ID: 21337993
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B; Pahwa R; Lyons KE
    J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.
    Pagonabarraga J; Kulisevsky J; Llebaria G; García-Sánchez C; Pascual-Sedano B; Gironell A
    Mov Disord; 2008 May; 23(7):998-1005. PubMed ID: 18381647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of Parkinson disease.
    Stacy M
    Neurol Clin; 2009 Aug; 27(3):605-31, v. PubMed ID: 19555824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
    Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
    Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

  • 12. Anxiety disorders in Parkinson's disease: prevalence and risk factors.
    Dissanayaka NN; Sellbach A; Matheson S; O'Sullivan JD; Silburn PA; Byrne GJ; Marsh R; Mellick GD
    Mov Disord; 2010 May; 25(7):838-45. PubMed ID: 20461800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.
    Bhatia K; Brooks DJ; Burn DJ; Clarke CE; Playfer J; Sawle GV; Schapira AH; Stewart D; Williams AC
    Hosp Med; 1998 Jun; 59(6):469-80. PubMed ID: 9775275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive aspects of cognitive dysfunction in Parkinson's disease.
    Growdon JH; Corkin S; Rosen TJ
    Adv Neurol; 1990; 53():365-76. PubMed ID: 1978518
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuropharmacological treatment of mental dysfunction in Parkinson's disease.
    McNamara P; Durso R
    Behav Neurol; 2006; 17(1):43-51. PubMed ID: 16720959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical treatment of Parkinson's disease in elderly and multimorbid patients].
    Lettow I; Röther J
    Internist (Berl); 2014 Jun; 55(6):728-34. PubMed ID: 24806271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for Parkinson's disease.
    Chen JJ; Swope DM
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
    Crispo JA; Fortin Y; Thibault DP; Emons M; Bjerre LM; Kohen DE; Perez-Lloret S; Mattison D; Willis AW; Krewski D
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1011-9. PubMed ID: 26081062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.